Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LivaNova (LIVN) Cash & Equivalents (2016 - 2025)

LivaNova's Cash & Equivalents history spans 12 years, with the latest figure at $738.4 million for Q1 2025.

  • For Q1 2025, Cash & Equivalents rose 138.83% year-over-year to $738.4 million; the TTM value through Mar 2025 reached $738.4 million, up 138.83%, while the annual FY2024 figure was $428.9 million, 37.73% up from the prior year.
  • Cash & Equivalents for Q1 2025 was $738.4 million at LivaNova, up from $428.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $738.4 million in Q1 2025 and bottomed at $181.8 million in Q3 2021.
  • The 5-year median for Cash & Equivalents is $308.9 million (2023), against an average of $326.2 million.
  • The largest annual shift saw Cash & Equivalents decreased 25.11% in 2023 before it soared 138.83% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $181.8 million in 2021, then surged by 65.77% to $301.4 million in 2022, then increased by 3.29% to $311.4 million in 2023, then soared by 37.73% to $428.9 million in 2024, then skyrocketed by 72.19% to $738.4 million in 2025.
  • Per Business Quant, the three most recent readings for LIVN's Cash & Equivalents are $738.4 million (Q1 2025), $428.9 million (Q4 2024), and $320.2 million (Q3 2024).